Use of siRNA targetting SIPA1L1 for the reduction of adipogenesis
US8759311B2 · kind B2 · utility
0Cited by
1References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 1, 2010 |
| Grant date | Jun 24, 2014 |
| Priority date | — |
| Expiry date | Oct 1, 2030 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/531
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention concerns Sipa1l1, a new target involved in adipogenesis modulation. Using a siRNA approach, the inventors demonstrated that decrease in Sipa1l1 activity in preadipocytes and adipose tissue induces a decrease in adipogenesis. Thus, the present invention relates to modulators of Sipa1l1 activity as well as screening test for identification of modulators of the activity of this target, and their use, especially in pharmaceutical composition, to modulate adipogenesis and thus treat obesity and related disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.